Efficacy of Rheocarna<sup>®</sup>, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia
Apheresis with the Rheocarna in patients with no- or poor-option CLTI reduced LDL-C and fibrinogen levels and improved ABI and SPP, achieving a 1-year wound healing rate of 60.7%. This novel approach could provide additional treatment options for conventional CLTI.
Authors
- Yoshimitsu Soga (ORCID: https://orcid.org/0000-0003-1931-5769)
- Daizo Kawasaki (ORCID: https://orcid.org/0000-0002-4413-6773)
- Masahiko Fujihara (ORCID: https://orcid.org/0000-0002-7001-9220)
- Mitsuyoshi Takahara (ORCID: https://orcid.org/0000-0001-5105-041X)
- Amane Kozuki (ORCID: https://orcid.org/0000-0002-7723-3625)
- Kazunori Horie (ORCID: https://orcid.org/0000-0002-8614-7729)
- Yasutaka Yamauchi (ORCID: https://orcid.org/0000-0002-1440-6349)
- Tatsuro Takei (ORCID: https://orcid.org/0000-0001-8733-473X)
- Osamu Iida
Institutions
- Saiseikai Nakatsu Hospital (JP)
- Kishiwada Tokushukai Hospital (JP)
- Morinomiya Hospital (JP)
- Kokura Memorial Hospital (JP)
- Takatsuki General Hospital (JP)
- Sendai Kousei Hospital (JP)
- Osaka International University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1253/circj.cj-24-0830
- Citations
- 8
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 16.05